Safe Administration of Fruquintinib in a Hemodialysis Patient with Metastatic Colorectal Cancer: A Case Report
This case suggests that fruquintinib may be administered safely to selected patients with mCRC on maintenance hemodialysis. Further data are needed to establish dosing strategies and monitor potential toxicities in this population.
Authors
- Koichi Suyama (ORCID: https://orcid.org/0000-0002-1823-2059)
- Yuko Tanabe (ORCID: https://orcid.org/0000-0001-9279-5952)
- Haruka Kono (ORCID: https://orcid.org/0000-0002-6554-7037)
- Aoi Kuroda (ORCID: https://orcid.org/0000-0002-8751-9600)
- Kohji Takemura (ORCID: https://orcid.org/0000-0002-3697-9180)
- Yuki Murakawa
- Takeshi Yamaguchi (ORCID: https://orcid.org/0000-0001-6329-0437)
- Keita Uchino
- Masahito Suemasu
Institutions
- Toranomon Hospital (JP)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1159/000549871
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00